SUMMARY OF THE OBJECTIONS IN THE LETTER TO THE EDITOR
In the letter 1 sent to Neurosurgery by Zou et al regarding our grading system, the main criticisms are the following: the absence of a pathological subtype characterization of the skull base chordomas and the absence of biomarkers such as brachyury-YAP. Finally, the commentator 1 cites some recent studies in the molecular biology of chordomas that, in the words of the commentators, constitute "a growing body of evidence supporting the use of the immune [sic] parameters as powerful prognostic tool in cancers." This refers again to a biomarker for chordomas.
OUR RESPONSE
The main purpose of a grading system is to help neurosurgeons to make surgical decisions prior to the procedure itself. With that in mind, the criteria of the Sekhar Grading System for Cranial Chordomas (SGSCC) are as follows: tumor size, site, vascular involvement, intradural invasion, and tumor regrowth after prior treatment. 2 These criteria are the type of information that is readily available to any neurosurgeon before planning a surgical procedure. The criterion prior treatment is an interaction between biological aggressiveness of the chordoma and incomplete resection due to an inadequate choice of the surgical approach, if that is the case for a particular patient. Therefore, the SGSCC purposely did not include any advanced molecular or pathological markers because these are not currently available prior to the surgical intervention itself. Still, at the end of our original publication, 2 we specifically addressed that future developments in the genetic knowledge of chordomas could lead to reappraisal of the classification. There are some important points to be addressed regarding the use of molecular biology markers. It is well known that stereotactic-guided biopsy cannot provide an accurate diagnosis, 5 that all the molecular markers are tissue dependent, and that there is a great heterogeneity in any tumor sample sent to pathological analysis. Therefore, surgical resection is necessary for a full tumor characterization and for any immune-histochemical analysis, or other types of molecular profiling. An ideal tumor prognostic marker would be one that could be obtained preoperatively and would have a high specificity and sensitivity. Currently that is not the case, although through advanced biophysical methods such as Raman spectroscopy 6, 7 this might be possible in the future.
PROGNOSTIC FACTORS
As mentioned above, the ideal molecular prognostic factor would be one that in addition to high sensitivity and high specificity could be obtained easily preoperatively. The experience with meningiomas provides a good template for the evolution of molecular markers and the current problems faced by neurosurgeons when confronted with a case. The original Simpson classification for meningiomas was published in 1957; 8 over the years, many authors have published on molecular markers for meningiomas. Perry et al 9 included a preoperative radiological criterion and a postoperative histological marker when looking into the survival of patients diagnosed with meningiomas. Later, in 2004, Perry, Gutman, and Reifenberg 10 stated: "A better understanding of the molecular mechanisms involved in meningioma pathogenesis may not only lead to the identification of novel diagnostic and prognostic marker but will also facilitate the development of new pathogenesis-based therapeutic strategies". 10 Following that, innumerable studies have been published on molecular markers for meningiomas. However, Nanda et al 11 recently showed that the degree of surgical resection of the meningiomas still represented the most important factor for recurrence free survival and that the Simpson classification was still relevant.
Chordomas are rare tumors, but efforts are being made to understand their pathogenesis. Thus, in addition to brachyury-YAP and the other studies cited by Zou et al, 1 we would like to mention some other recent developments regarding molecular markers for chordomas. Regarding brachyury (transcription factor T), Pillay et al 12 confirmed that a single nucleotide variant of gene T (chromosome 6q27) is implicated in the pathogenesis of chordomas and the duplication of the T gene is associated with familial risk. Other possible markers for chordomas include loss of heterozygosity at the phosphatase and tensin homolog, 13 cathepsin K, 14 which is associated with chordoma invasion and reduced progression-free survival, and SMARCB1/INI1. 15 Recently Hasselblatt et al 16 reported that chordomas with SMARCB1/INI1 loss are a distinct molecular entity with dismal prognosis. Similar to other types of cancer, in chordoma cell lines, it seems that there is a role of long noncoding RNA LOC554202 for chordoma cell proliferation and invasion. 17 Additionally, MicroRNA possibly will play a very important role in the understanding of the molecular pathways of chordomas. 18 Therefore, the biology of chordomas is complex, many groups were able to find markers that will eventually translate in a better understanding prognosis in a similar fashion to oligodendrogliomas.
CONCLUSION
The ideal prognostic grading system would factor clinical and molecular features prior to surgery for any type of tumor, currently that is not possible. However, the SGSCC incorporates all the relevant anatomic, radiological, and clinical features. 2 Now any neurosurgeon around the world can easily predict the difficulty of the case and know which areas of the skull base will need attention and further therapy. The grading system was planned as such that new developments in the technology for molecular markers can be easily incorporated into it.
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